<DOC>
	<DOCNO>NCT00324779</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Giving rituximab chemotherapy may effective treatment B-cell non-Hodgkin 's lymphoma B-cell acute lymphoblastic leukemia . PURPOSE : This phase II trial study well rituximab work treat young patient plan receive chemotherapy B-cell non-Hodgkin 's lymphoma B-cell acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Rituximab Treating Young Patients Who Are Receiving Chemotherapy B-Cell Non-Hodgkin 's Lymphoma B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate child adolescents B-cell non-Hodgkin 's lymphoma ( B-NHL ) B-cell acute lymphoblastic leukemia ( B-ALL ) treat rituximab monotherapy upfront window therapy chemotherapy . - Evaluate effect rituximab different histological subtypes childhood mature B-NHL B-ALL patient treat regimen . - Investigate rituximab response patient treat regimen . - Determine toxicity profile rituximab patient . - Collect pharmacokinetic pharmacodynamic data patient treat regimen . OUTLINE : This multicenter study . Patients receive rituximab IV day 1 . PROJECTED ACCRUAL : A total 79 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically immunohistochemically OR cytomorphologically immunphenotypically confirm mature Bcell nonHodgkin 's lymphoma Bcell acute lymphoblastic leukemia CD20 positive disease PATIENT CHARACTERISTICS : Not pregnant nursing Fertile patient must use effective contraception Adequate general condition sufficient organ function ( hepatic , renal , cardiac ) No known disease would preclude protocol therapy rituximab No known allergy proteins No acute previous hepatitis B infection PRIOR CONCURRENT THERAPY : At least 2 week since prior corticosteroid No prior radiotherapy No prior concurrent chemotherapy No concurrent treatment another investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
</DOC>